Mesoblast (MESO) Return on Capital Employed (2017 - 2023)
Mesoblast's (MESO) quarterly Return on Capital Employed came in at 110.04% in Q2 2023, up 10803.0% year-on-year from N/an in Q2 2022, and down 1.75% quarter-over-quarter from 112.0% in Q1 2023.
Mesoblast (MESO) Return on Capital Employed (2017 - 2023) Analysis & Trends
Mesoblast has disclosed Return on Capital Employed across 7 years of filings, most recently posting 110.04% for Q2 2023.
- Return on Capital Employed for Q2 2023 came in at 110.04%, up 10803.0% year-over-year; the trailing twelve-month figure through Jun 2023 was 110.04% (up 10803.0% YoY), and the FY2025 annual result was 9.94%, up 92.0% from the prior year.
- Return on Capital Employed came in at 110.04% for Q2 2023 at Mesoblast, down from 112.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 822.31% in Q2 2021 to a low of 368.88% in Q1 2020.
- The 5-year median for Return on Capital Employed is 106.1% (2021), against an average of 102.43%.
- Across the five-year window, Return on Capital Employed jumped 83040 bps in 2021 and tumbled 82031 bps in 2022, its largest moves.
- Mesoblast's Return on Capital Employed stood at 306.35% in 2019, then surged by 158 bps to 176.64% in 2020, then jumped by 195 bps to 521.85% in 2021, then sank by 72 bps to 143.58% in 2022, then slipped by 23 bps to 110.04% in 2023.
- The last three Return on Capital Employed figures came in at 110.04% (Q2 2023), 112.0% (Q1 2023), and 143.58% (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 110.04% |
| Mar 31, 2023 | 112.00% |
| Dec 31, 2022 | 143.58% |
| Sep 30, 2022 | 119.17% |
| Jun 30, 2022 | 2.00% |
| Mar 31, 2022 | 627.50% |
| Dec 31, 2021 | 521.85% |
| Sep 30, 2021 | 688.27% |
| Jun 30, 2021 | 822.31% |
| Mar 31, 2021 | 102.16% |
| Dec 31, 2020 | 176.64% |
| Sep 30, 2020 | 52.05% |
| Jun 30, 2020 | -8.09% |
| Mar 31, 2020 | -368.88% |
| Dec 31, 2019 | -306.35% |
| Sep 30, 2019 | -308.73% |
| Jun 30, 2019 | -325.95% |
| Mar 31, 2019 | -315.81% |
| Dec 31, 2018 | -314.82% |
| Sep 30, 2018 | -412.89% |